Pfizer’s Ibrance has been approved for use by the NHS in Scotland as a second-line treatment for advanced breast cancer after hormonal therapy. The Scottish Medicines Consortium (SMC) said Ibrance – a CDK4/6 inhibitor – can increase the time befor...
Original Article: Scotland backs Pfizer’s Ibrance for breast cancer